Ankylosing Spondylitis - Global Strategic Business Report

The global market for Ankylosing Spondylitis was estimated at US$6.0 Billion in 2024 and is projected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Ankylosing Spondylitis market.

Global Ankylosing Spondylitis Market - Key Trends & Drivers Summarized

Why Is Ankylosing Spondylitis Becoming a Critical Global Health Concern?

Ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, is gaining recognition as a significant global health concern due to its debilitating nature and long-term impact on quality of life. AS primarily affects young adults, with symptoms often beginning in the late teens or early twenties. The progressive nature of the disease, characterized by chronic pain, stiffness, and potential spinal fusion, underscores the need for effective therapeutic interventions to manage symptoms and prevent complications. Moreover, the rising prevalence of ankylosing spondylitis worldwide has led to increased demand for targeted treatment options. While the exact cause of AS remains unclear, genetic predisposition, particularly the presence of the HLA-B27 gene, has been identified as a major risk factor. This has prompted advancements in precision medicine approaches, enabling tailored treatment strategies for individuals with AS. Additionally, the societal and economic burden of the disease, including loss of productivity and healthcare costs, has heightened the focus on improving access to effective therapies.

What Advancements Are Driving the Development of AS Treatments?

The treatment landscape for ankylosing spondylitis has evolved significantly, driven by advancements in biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Tumor necrosis factor (TNF) inhibitors, such as adalimumab and infliximab, have been pivotal in transforming the management of AS by reducing inflammation, slowing disease progression, and improving patient outcomes. The introduction of interleukin (IL)-17 inhibitors, including secukinumab and ixekizumab, has further expanded treatment options, particularly for patients who do not respond to TNF inhibitors. Innovations in drug delivery systems, such as self-administered subcutaneous injections and extended-release formulations, have improved patient compliance and convenience. Furthermore, advancements in diagnostic tools, including magnetic resonance imaging (MRI) and genetic testing, are facilitating earlier detection of AS, enabling timely intervention and better disease management. Ongoing research into novel therapeutic targets, such as Janus kinase (JAK) inhibitors, holds promise for expanding the range of effective treatment options in the near future.

How Are Regional Dynamics Influencing Market Growth?

The ankylosing spondylitis market exhibits significant regional variations, influenced by differences in disease prevalence, healthcare infrastructure, and access to advanced treatments. North America dominates the market, driven by a high prevalence of autoimmune diseases, robust healthcare systems, and substantial investments in research and development. The region also benefits from favorable reimbursement policies and widespread availability of advanced biologic therapies. Europe follows closely, with a strong focus on early diagnosis and the integration of innovative treatments into standard care protocols. Countries such as Germany, the UK, and France have well-established rheumatology networks, ensuring better disease management and patient outcomes. In the Asia-Pacific region, the market is expanding rapidly due to increasing disease awareness, improving healthcare access, and rising disposable incomes. Emerging economies such as China and India are witnessing growing adoption of biologic therapies, supported by government initiatives to enhance healthcare infrastructure. Meanwhile, Latin America and the Middle East are gradually embracing advanced treatments, although challenges related to affordability and awareness persist.

What Is Driving Growth in the Ankylosing Spondylitis Market?

The growth in the ankylosing spondylitis market is driven by several factors, including the rising prevalence of autoimmune and inflammatory diseases, advancements in biologic therapies, and increasing awareness of the importance of early diagnosis. The growing adoption of TNF inhibitors and IL-17 inhibitors as first-line treatments has significantly improved patient outcomes, fueling market expansion. Additionally, the development of next-generation therapies, including JAK inhibitors and other novel biologics, is addressing unmet needs in AS management. Consumer demand for more convenient and effective treatment options, such as self-administered injections, has spurred innovation in drug delivery systems. Regional government initiatives to improve healthcare access and affordability, particularly in emerging markets, are further driving the adoption of advanced therapies. Moreover, the integration of digital health tools, including telemedicine and remote monitoring, is facilitating better disease management and treatment adherence. These factors collectively highlight the robust growth trajectory of the ankylosing spondylitis market and its critical role in addressing the global burden of this chronic condition.

Scope of Study:

The report analyzes the Ankylosing Spondylitis market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Drug Class (TNF Inhibitors Drug Class, NSAIDs Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the TNF Inhibitors Drug Class segment, which is expected to reach US$4.4 Billion by 2030 with a CAGR of a 6.1%. The NSAIDs Drug Class segment is also set to grow at 4.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $1.6 Billion in 2024, and China, forecasted to grow at an impressive 8.4% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Ankylosing Spondylitis Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Ankylosing Spondylitis Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Ankylosing Spondylitis Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie, Inc., Akeso Biopharma Co., Ltd., Amgen, Inc., Coherus Biosciences, Inc., Eli Lilly and Company and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 34 companies featured in this Ankylosing Spondylitis market report include:

• AbbVie, Inc.
• Akeso Biopharma Co., Ltd.
• Amgen, Inc.
• Coherus Biosciences, Inc.
• Eli Lilly and Company
• Johnson & Johnson Innovative Medicine UK
• Novartis Pharmaceuticals Corporation
• Pfizer, Inc.
• Trinity Biotech PLC
• UCB SA
• ViennaLab Diagnostics GmbH
• Zydus Lifesciences Limited

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.